Repository logo
 

GM-CSF targeting in COVID-19, an approach based on fragile foundations.

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Kohler, Katharina 
Morris, Andrew Conway  ORCID logo  https://orcid.org/0000-0002-3211-3216

Abstract

Trials of anti-GM-CSF therapies in COVID-19 show divergent results, this may be explained by underlying biology and the fragility of the study findings. Further investigation of the pathophysiology of COVID-19 is required to better target therapies.

Description

Keywords

Journal Title

Eur Respir J

Conference Name

Journal ISSN

0903-1936
1399-3003

Volume Title

Publisher

European Respiratory Society (ERS)
Sponsorship
MRC (MR/V006118/1)
KK is supported by grants from the Academy of Medical Sciences (SG023\1048) and NIHR Development and Skills Enhancement award (NIHR 302841). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. ACM is supported by a Clinician Scientist Fellowship from the Medical Research Council (MR/V006118/1).